Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6791759 | 0.87 | OPRD1 (0.53) | OPRD1OPRK1OPRM1 | |
| SCHEMBL251637 | 0.86 | OPRD1 (0.50) | OPRD1OPRK1OPRM1 | |
| SCHEMBL8394426 | 0.85 | OPRD1 (0.59) | OPRD1OPRK1OPRM1 | |
| Hydrochloric Acid SCHEMBL6796027 | 0.84 | OPRD1 (0.58) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6796975 | 0.83 | OPRD1 (0.53) | OPRD1OPRK1OPRM1 | |
| SCHEMBL8009424 | 0.79 | CYP3A4 (0.54) | OPRD1OPRK1OPRM1 | |
| SCHEMBL4591245 | 0.79 | CYP3A4 (0.54) | OPRD1OPRK1OPRM1 | |
| SCHEMBL8002856 | 0.79 | CYP3A4 (0.54) | OPRD1OPRK1OPRM1 | |
| SCHEMBL7993545 | 0.79 | CYP3A4 (0.54) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6246739 | 0.74 | HSP90AA1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2249872-B1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9314463-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS | 2015-11-26 | — | — | US | disclosed |
| US-9061026-B2 | Oligomer-diarylpiperazine conjugates | NEKTAR THERAPEUTICS (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140155412-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155412-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | OPRD1 2294/4885OPRK1 1249/4885OPRM1 574/4885 |
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | BIRC5, MTX2, IAPP | OPRD1 2294/4885OPRK1 1249/4885OPRM1 574/4885 |
| US-20150335640-A1 | OLIGOMER-DIARYLPIPERAZINE CONJUGATES | BIRC5, MTX2, IAPP | OPRD1 2294/4885OPRK1 1249/4885OPRM1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.